Pfizer Korea to launch an anti-cancer drug, Sutent.

Published: 2007-03-15 06:59:00

Updated: 2007-03-15 06:59:00

Pfizer Korea celebrated the market launching of Sutent (sunitinib maleate), a multiple targeted anti-cancer drug, in attendance of the top company executives and other 100 staffs at Grand hotel Hongjaedong, on March 9 for the objectives of shedding their vision with anti-cancer drug business.

...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK